An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons

Inclusion Criteria: * \> 18 years old * HIV-1 seropositive * CD4 count\>250 cell/mm3 * Detectable HIV-1 plasma viral load * HSV-1 \& 2 seronegative. * Not on HIV antiretroviral therapy or planning to initiate antiretroviral therapy during the study period. * Not intending to move out of the area for duration of study participation * Willing and able to provide independent written informed consent. * Willing and able to undergo clinical evaluations. * Willing and able to take study drug as directed. * Willing and able to adhere to follow-up schedule Exclusion Criteria: * Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir. * Use of ganciclovir, foscarnet, or cidofovir * History of evidence of CMV disease * Known medical history of seizures * Known renal insufficiency, defined as serum creatine \>1.5 mg/dl * AST or ALT \>3times upper limit of normal * Hematocrit \<30% * Neutropenia, defined as absolute neutrophil count \<1000 * Thrombocytopenia, defined as platelet count \<75,000 * History of thrombotic microangiopathy * For women, pregnancy as confirmed by a urine pregnancy test * Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study